Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SERONO'S METRODIN IS APPROVED FOR SECOND-LINE TREATMENT OF INFERTILITY

Executive Summary

SERONO'S METRODIN IS APPROVED FOR SECOND-LINE TREATMENT OF INFERTILITY in women with polycystic ovarian syndrome. The package insert for Metrodin (human follicle stimulating hormone), approved by FDA on Sept. 18, states: "Metrodin and hCG [human chorionic gonadotropin] given in a sequential manner are indicated for the induction of ovulation in patients with polycystic ovarian disease who have an elevated LH/FSH ratio and who have failed to respond to adequate clomiphene citrate therapy." Patients must meet the following criteria before going on Metrodin treatment: a gynecologic and endocrinologic evaluation, exclusion of primary ovarian failure or early pregnancy, cervical dilation and curettage, and evaluation of the husband's fertility potential. Adverse reactions with Metrodin have occurred in "approximately 1 in 10" patients; the most common reactions are hyperstimulation syndrome, ovarian enlargement, abdominal pain, and rash or swelling at the site of injection, the insert said. FDA classified Medtrodin as a 2 C product (a new salt or esther representing little or no therapeutic gain). In a press release, Serono maintained that Metrodin is the first product for treating infertility approved by the FDA in five years. Metrodin will become available to wholesalers on Nov. 1 at a price of $35.20 per amp.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

LL1135489

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel